Drugs / TPST-1120
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03829436 | Mar 2019 → Sep 2022 | cholangiocarcinoma, colorectal cancer, gastroesophageal cancer, head and neck squamous cell carcinoma +8 | Tempest Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04524871 | Nov 2020 → Jul 2027 expected | liver cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06680258 | Dec 2025 → Dec 2028 expected | hepatocellular carcinoma | Tempest Therapeutics | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TPST-1120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06680258 ↗ |
| Action | Inhibit | “TPST-1120, a small molecule selective antagonist of PPARα (peroxisome proliferator activated receptor alpha)” NCT03829436 ↗ |
| Modality | Small molecule | “TPST-1120, a small molecule selective antagonist of PPARα (peroxisome proliferator activated receptor alpha)” NCT03829436 ↗ |
| Route | Oral | “TPST-1120 administered orally” NCT03829436 ↗ |
| Target | PPARA | “TPST-1120, a small molecule selective antagonist of PPARα (peroxisome proliferator activated receptor alpha)” NCT03829436 ↗ |